UPLOAD Filing
Artiva Biotherapeutics, Inc.
Date: Aug. 11, 2025 · CIK: 0001817241 · Accession: 0000000000-25-008421
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-289325
Letter
Re: Artiva Biotherapeutics, Inc. Registration Statement on Form S-3 Filed August 6, 2025 File No. 333-289325 Dear Fred Aslan M.D.:
August 11, 2025
Fred Aslan, M.D. President and Chief Executive Officer Artiva Biotherapeutics, Inc. 5505 Morehouse Drive, Suite 100 San Diego, CA 92121
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Carlos Ramirez, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> August 11, 2025 Fred Aslan, M.D. President and Chief Executive Officer Artiva Biotherapeutics, Inc. 5505 Morehouse Drive, Suite 100 San Diego, CA 92121 Re: Artiva Biotherapeutics, Inc. Registration Statement on Form S-3 Filed August 6, 2025 File No. 333-289325 Dear Fred Aslan M.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Carlos Ramirez, Esq. </TEXT> </DOCUMENT>